Canntab Therapeutics director resigns | S&P Global Market Intelligence

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
WebinarM&A In Focus: Tech Acquisitions and the ‘New Normal’ in 2023
- 02/08/2023
- Live, Online
- 11:00 am - 12:00 pm EST
Webinar ReplaysAssessing the impact of the U.S. Government Accountability Office recommendations’ on Export Control Compliance at universities
- 01/18/2023
- On-Demand
- 60 minutes
ConferenceTPMTech
- 02/23/2023
- Hilton Long Beach Convention Center
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

Canntab Therapeutics director resigns

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

15 Jun, 2018 | 02:06

Canntab Therapeutics director resigns

Author Vince Iral
Theme Healthcare & Pharmaceuticals

Canntab Therapeutics Ltd. said Sheldon Inwentash resigned from its board to pursue other opportunities.

The Canada-based company develops advanced pharmaceutical-grade formulations of cannabinoids.